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Abstract
For antiviral drug design, especially in the field of influenza virus research, potent multivalent inhibitors raise high expectations for
combating epidemics and pandemics. Among a large variety of covalent and non-covalent scaffold systems for a multivalent
display of inhibitors, we created a simple supramolecular platform to enhance the antiviral effect of our recently developed antiviral
Peptide B (PeBGF), preventing binding of influenza virus to the host cell. By conjugating the peptide with stearic acid to create a
higher-order structure with a multivalent display, we could significantly enhance the inhibitory effect against the serotypes of both
human pathogenic influenza virus A/Aichi/2/1968 H3N2, and avian pathogenic A/FPV/Rostock/34 H7N1 in the hemagglutination
inhibition assay. Further, the inhibitory potential of stearylated PeBGF (C18-PeBGF) was investigated by infection inhibition assays,
in which we achieved low micromolar inhibition constants against both viral strains. In addition, we compared C18-PeBGF to other
published amphiphilic peptide inhibitors, such as the stearylated sugar receptor mimicking peptide (Matsubara et al. 2010), and the
“Entry Blocker” (EB) (Jones et al. 2006), with respect to their antiviral activity against infection by Influenza A Virus (IAV) H3N2.
However, while this strategy seems at a first glance promising, the native situation is quite different from our experimental model
settings. First, we found a strong potential of those peptides to form large amyloid-like supramolecular assemblies. Second, in vivo,
the large excess of cell surface membranes provides an unspecific target for the stearylated peptides. We show that acylated
peptides insert into the lipid phase of such membranes. Eventually, our study reveals serious limitations of this type of self-assem-
bling IAV inhibitors.
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Introduction
Annually influenza A virus infections cause up to 500.000
deaths worldwide, and are therefore a serious threat, and burden
to humans [1]. Hence, research and development of new afford-
able influenza antivirals are an important task to combat not
only seasonal epidemics, but also devastating pandemics. For
therapy of infected patients, several pharmaceuticals targeting
influenza neuraminidase (oseltamivir, zanamivir) or the proton
channel protein M2 (amantadine, rimantadine) are available.
However, the efficiencies of these drugs are competing with fast
and continuously changing phenotypes of the influenza virus
[2].
Among different strategies to block virus entry [3], several
multivalent inhibitors preventing binding of the influenza virus
to the host cell proved to be potent drug candidates [4-9]. Those
inhibitors bind to the virus envelope spike protein hemagglu-
tinin (HA) which is organized as a homotrimer. In particular,
inhibitors competing for the highly conserved binding site for
sialic acid, which is the natural receptor presented on the host
cell surface have been applied. Essentially, these approaches
revealed that an efficient block of virus binding requires a
multivalent interaction between virus and inhibitors. This can
be rationalized by the fact that a stable binding of influenza
virus to the host cell is mediated by a multivalent interaction
between HA binding pockets and cell surface receptors as a
monovalent interaction is too weak for stable binding [10,11].
Peptide-based self-assembled nanostructures can be used as the
simplest platform for the multivalent display of ligands,
although this approach has not been explored much in the
context of virus inhibition. There are only a few reports on
using peptide based self-assembly for influenza virus inhibition
[12-14].
The entry blocker (EB) which is a peptide fragment derived
from the fibroblast growth factor signal sequence 4 (FGF) has a
rather broad antiviral activity among several influenza strains in
the micromolar range [14]. It has been shown that EB can bind
to HA, and causes viral aggregation, which has been ascribed to
multimerization of EB monomers providing a multivalent
surface [15,16]. However, the inhibitory mechanism has not
been elucidated in detail.
Matsubara et al. introduced a sugar mimetic peptide, which
binds to the sialic acid binding pocket of HA [13]. In order to
increase the inhibitory capacity of the peptide, a stearyl group
has been attached to the mimetic peptide, presumably leading to
the formation of a supramolecular assembly, which allows
multivalent interactions. By that, multivalent inhibitors could be
designed with antiviral activity in the low micromolar range.
Recently, we identified an antiviral peptide, which we derived
from the paratope region of an antibody directed against HA
binding to the sialic acid binding pocket. The peptide was
shown to bind still to this site, and inhibits different influenza A
virus strains in binding, and infection being superior to other
antiviral peptides. We demonstrated inhibitory performance in
the micromolar range against the serotypes of human patho-
genic influenza A/Aichi/2/1968 H3N2 (X31) and avian patho-
genic A/FPV/Rostock/34 H7N1. Inspired by the strategy of
Matsubara et al. we attached a C18 fatty acid chain to this
peptide, called PeBGF, to assemble multivalent structures which
enhanced the antiviral potential compared to the monomeric
form. In this study, stearylated PeBGF (C18-PeBGF) has been
compared with EB, the stearylated sialic acid mimetic (C18-
s2s), and the stearylated control peptide with the reverse amino
acid sequence (C18-rs2s) in respect to their potential to inhibit
virus mediated hemagglutination, and to lyse red blood cells.
Results and Discussion
Peptide synthesis and characterization
Peptide synthesis was performed using a rink amide resin on an
automatic synthesizer by the Fmoc/tert-butyl strategy [17,18].
The N-terminus of the N-terminal free resin bound peptide was
acylated with stearic acid using O-(benzotriazol-1-yl)-
N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) as
coupling reagent in the presence of diisopropylethylamine
(DIPEA) in DMF. Peptides summarized in Table 1 were
explored for influenza A virus inhibition.








Entry blocker (EB) RRKKAAVALLPAVLLALLAP-
CONH2
aPatent application is in progress [19]. The sequence will be revealed
soon, by a publication in another journal.
Acylated and other amphiphilic peptides are well known to self-
assemble into supramolecular structures [20,21]. Stearylated
peptides, closely related to C18-s2s, C18-rs2s and C18-PeBGF
assemble as supramolecular structures with a critical micelle
concentration (CMC) between 0.8–0.9 µM and a size between
0.2 and 2.3 µm depending on the peptide concentration [12].
The rather large size indicates the formation of rather large
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Figure 2: Negative staining transmission electron micrographs (TEM) of fibrillar (left) and sheet-like structures (right) of C18-PeBGF (2 mM in PBS),
scale bars correspond to 25 nm.
structures different from a simple sphere-like micelle. To verify
and characterize the assembly of our peptides into higher-order
structures, we studied exemplarily the organization of C18-
PeBGF by dynamic light scattering (DLS) and transmission
electron microscopy (TEM).
First, the size of the supramolecular nanostructures formed by
C18-PeBGF, C18-s2s, and C18-rs2s was analyzed by DLS at
low concentration of 20 µM in PBS (10 mM, pH 7.4). For the
analysis of C18-PeBGF, we observed a hydrodynamic diameter
of 16.7 nm (PDI = 0.454) along with 10–15% bigger supra-
molecular structures with hydrodynamic diameters of 184.3 nm
and 573.1 nm as per volume distribution profile (Figure 1). We
observed much bigger aggregates in the case of C18-rs2s with a
hydrodynamic diameter of 818.8 nm (PDI = 0.328). The volume
size distribution was multimodal for C18-s2s showing higher-
order aggregates of different sizes at 20 µM concentration (see
Supporting Information File 1).
To address if the tendency of C18-PeBGF to form larger supra-
molecular structures becomes prominent at higher concentra-
tions, we analyzed C18-PeBGF in DLS measurements at a
concentration of 100 µM, too. Indeed, under those conditions
we observed supramolecular aggregates with a size larger than
1 µm indicating the strong potential of C18-PeBGF to organize
as rather large assemblies. To visualize the organization of
those assemblies, we employed TEM. To facilitate the structure
Figure 1: Volume size distribution profile of C18-PeBGF at a concen-
tration of 20 µM in PBS (10 mM, pH 7.4).
identification, we used an even higher concentration of C18-
PeBGF. We found a fibrillar supramolecular arrangement being
up to several hundred nanometers long at 2 mM peptide concen-
trations (Figure 2). These fibers appeared predominantly as
single, rather elongated structures. However, we found sheet
like structures, possibly from a side-by-side assembly of these
fibers, too. Importantly, cryo-TEM provides the same results
(not shown) showing that formation of the large assemblies is
Beilstein J. Org. Chem. 2015, 11, 589–595.
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Table 2: Inhibition constants for inhibition of virus mediated hemagglutination (KiHAI) and for inhibitor caused agglutination (KiA).
Compound C18-PeBGF C18-s2s C18-rs2s EB
KiHAI (Aichi H3N2) [µM] 1.2 ± 0.0 0.8 ± 0.5 no effect 1.6 ± 0.3
KiHAI (Rostock H7N1) [µM] 2.8 ± 0.9 n.d. n.d. n.d.
KiA [µM] 100.0 ± 0.0 7.0 ± 0.8 4.1 ± 2.1 8.6 ± 7.0
The KiHAI represents the lowest concentration needed for full hemagglutination inhibition. The KiA value reflects the minimum concentration for agglu-
tination caused by the inhibitor itself. The shown values represent the mean of at least three independent experiments. Extended values represent the
standard error of the mean (SEM). n.d. (not determined).
not caused by contrast material. Preliminary TEM studies indi-
cate similar assemblies for the other peptides used here.
Our results indicate that the amphiphilic peptides do not behave
like typical micelle-forming molecules. Although we found
smaller supramolecular assemblies at 20 µM C18-PeBGF, there
is a strong tendency to form larger and stable supramolecular
arrangements. Indeed, our TEM images implicate a rather
amyloid-like character of C18-PeBGF and other amphiphilic
peptides used here. Notably, such larger structures are consis-
tent with the observation of Matsubara et al. at least with
respect to the dimension. Although the authors did not visu-
alize the morphology of their structures, the DLS data of this
report indicate different sized assembly forms even in the µm
range.
Amphiphilic peptides cause aggregation of
viruses
For the stearylated peptide s2s and the polar peptide EB binding
to influenza HA has been demonstrated [13,14]. In accordance
with the study of Matsubara et al. we used the reverse peptide
rs2s from the sialic acid mimetic as a control which does not
recognize the sialic acid binding pocket and thus does not bind
to HA.
To prove whether stearylated PeBGF is able to interfere with
influenza virus activity, we first investigated its potential to
aggregate viruses and compared it with that of other
amphiphilic peptides (Table 1). To this end, fluorescently
labeled influenza A virus X31 has been incubated with
amphiphilic inhibitors at 100 µM concentrations and shortly
centrifuged. For all inhibitors, but the control compound C18-
rs2s a higher fluorescent signal in the pellet compared to the
supernatant was observed, indicating not only binding to viruses
but also aggregation of viruses caused by the inhibitors
(Figure 3). Jones et al. suggested that the inhibitory mechanism
of action of EB is based on its viral aggregation potential, which
has been supported by density gradient and electron microscopy
analysis [15]. Indeed aggregation of viruses can only be
explained by the formation of a supramolecular arrangement of
amphiphilic peptides forming a surface with multiple ligands
recognizing HA but not by a monomeric organisation of
amphiphilic peptides.
Figure 3: Amphiphilic inhibitors induce aggregation of viruses. R18
labeled influenza virus was incubated without or with inhibitors at
100 µM for 20 min at room temperature and subsequently centrifuged.
To supernatant and pellet, respectively, Triton-X100 was added, and
their fluorescence signal was recorded. Relative fluorescence indi-
cates fluorescence from pellet and supernatant in relation to the total
signal before centrifugation. Error bars represent the standard error of
the mean (SEM) of at least three independent experiments.
Amphiphilic peptides interfere with virus
binding to cells
The potential to inhibit binding of influenza viruses to cells can
be investigated by the well-established hemagglutination inhibi-
tion assay (HAI) [22]. All peptides, but the control peptide C18-
rs2s were able to inhibit Aichi H3N2 virus mediated hemagglu-
tination already at low micromolar concentrations (Table 2).
For EB an IC50 of 20 µM against Aichi H3N2 in the HAI has
been determined, however at higher viral titer than we used
[14].
However, we noted that inhibitors by themselves can trigger
unspecific hemagglutination. To quantify this behaviour, we
introduced another inhibitor constant (KiA), which represents
the minimum concentration to cause inhibitor triggered human
erythrocyte agglutination. While the multivalent organized
peptidic inhibitors inhibited virus mediated agglutination
Beilstein J. Org. Chem. 2015, 11, 589–595.
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already at low micromolar concentrations of about 1 µM, onset
of unspecific agglutination was observed at much higher
concentrations being in the range from 7 to 100 µM. It is impor-
tant to note that the unspecific interaction of our compounds
with cells can reduce the efficiency of compounds to prevent
virus binding to cells, possibly even by incorporation into the
lipid phase of membranes (see below).
In addition to the human pathogenic influenza A model strain
X31 (Aichi H3N2), we asked whether our inhibitor is able to
inhibit hemagglutination caused by the avian pathogenic strain
Rostock H7N1, too. Indeed, C18-PeBGF was able to inhibit
H7N1 completely at 2.8 µM concentrations (Figure 4). Thus, by
attaching stearyl to the N-terminus of the PeBGF sequence, we
could decrease the KiHAI value up by 10 fold for H7N1 and by
20 fold for Aichi H3N2 respectively (data not shown, see patent
[19]).
Figure 4: Inhibition constants KiHAI of C18-PeBGF, C18-s2s, C18-rs2s
and EB against Aichi H3N2 and Rostock H7N1 virus. The KiHAI
reflects the lowest concentration needed for full hemagglutination inhi-
bition. Error bars indicate the standard error of the mean (SEM) of at
least three independent experiments.
Protection from virus infection by acylated
peptide PeBGF
Next, we determined the potential of stearylated peptide PeBGF
for infection inhibition of MDCK cells by Aichi H3N2 and
Rostock H7N1. We found that C18-PeBGF inhibited the infec-
tion of cells at MOI 0.05 (1,500 pfu) with IC50 values of 84 µM
against Rostock H7N1, and 5.9 µM against Aichi H3N2
(Figure 5). In comparison to unmodified PeBGF the inhibitory
potential could be enhanced by approx. 5 fold against Aichi
H3N2, while the inhibition against Rostock H7N1 did not
increase (data not shown, see patent application [19]). These
results are in the same molar range found for the multivalent
assemblies of C18-s2s and EB. Jones et al. determined for EB
Figure 5: C18-PeBGF mediated protection from infection of MDCK
cells by Rostock H7N1 and Aichi H3N2. MDCK II cells were incubated
with viruses at an MOI of 0.05 for 24 h at 37 °C. Error bars indicate the
standard deviation of three experiments.
an IC50 of 4.5 µM against Hongkong H5N1 at an MOI of 0.05
48 h post infection.
Interaction with lipid membranes
Although the above presented data may be promising in terms
of efficient inhibition of influenza virus binding and, thus,
infection, we have to take into account that the conditions of
these experiments do not match the in vivo situation. Typically,
such antiviral compounds will be applied intravenously or by
inhalation to allow a systemic distribution or a tissue specific
targeting within the infected host. However, in those cases
amphiphilic peptides are in an environment of cell membrane
surfaces being in excess to viruses. Thus, the majority of
peptides will be incorporated into cell membranes. This would
be of significant negative consequences for application of those
peptides as antiviral drugs, because the multivalent presenta-
tion of the peptides would be prevented and one may speculate
that cell surface membrane associated peptides may act as an
additional receptor for virus attachment to the host cell surface.
Therefore, we studied the interaction of amphiphilic peptides
with membranes. To this end, we repeated our hemagglutina-
tion inhibition experiments, but we incubated the peptides with
100 nm large unilamellar vesicles (LUV) containing 6.25 nmol
DOPC for 30 minutes before virus and erythrocytes were added.
In that case the KiHAI increased by a factor of 2–4 (data not
shown; notably, a similar increase was found for KiA). This
suggests that the potential of inhibitors to prevent hemaggluti-
nation must have been partially neutralized by the liposomes,
either by attachment and/or incorporation into the lipid bilayer.
Very likely, in case of stearylated peptides, we surmise
incorporation into the bilayer via the fatty acyl chain.
Beilstein J. Org. Chem. 2015, 11, 589–595.
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Figure 6: Fluorescence microscopy images of GUVs (left) and human erythrocytes (right) after incubation with C18-s2s-TAMRA. The overlap of DIC
and rhodamine channels demonstrate the labeling of membranes by the fluorescent stearate peptide. Scale bars are in black.
To verify the association with lipid membranes exemplarily, we
synthesized the s2s construct with a terminal rhodamine fluo-
rophore. This compound was mixed with DOPC giant unil-
amellar vesicles (GUV) or human erythrocytes. In both cases
clear membrane labeling could be detected (Figure 6).
To assess how strong membrane incorporation of these peptides
can perturb membranes we measured their cell lytic activity in a
titration experiment with human erythrocytes. Apart from com-
pound C18-s2s which acted extremely hemolytic above concen-
trations of 20 µM, all peptides showed only low hemolytic
activity (Figure 7). For EB the same has been reported by Jones
et al. [16].
These results show that acylated peptides, e.g., C18-PeBGF,
could readily insert into biological membranes. As we observed
association with the plasma membrane of red blood cells we
surmise that those peptides could also insert into the virus enve-
lope.
Conclusion
Here, we investigated the potential of a stearylated HA anti-
body derived peptide, entitled C18-PeBGF to inhibit virus
binding to red blood cells, and to prevent from viral infection of
MDCK II cells. Based on the known capability of amphiphilic
peptides to organize as supramolecular structures, we intended
to enable a multivalent presentation of virus binding ligands
with enhanced antiviral activity. Although DLS analysis indi-
cated the presence of nanostructures at lower concentrations, as
the majority of detected objects showed an average diameter of
16.7 nm, we found already at 20 µM concentrations the forma-
tion of rather large supramolecular structures which are even
more prominent at higher concentrations. Structural analysis by
TEM revealed the presence of stable fiberlike assemblies,
which can further arrange side-by-side as sheets. Thus, acylated
Figure 7: Hemolytic activity of stearylated peptides and EB. 2%
human erythrocytes were incubated for one hour with peptides at
37 °C. After centrifugation, the hemolytic activity was assessed by
absorption measurement of the supernatant at 540 nm. Error bars indi-
cate the SEM of three titration experiments.
peptides as C18-PeBGF cannot be considered as micelle
forming molecules as it would be expected from the C18 chain.
We surmise that the peptide is an important structural determi-
nant leading to a rather amyloid-like assembly. This is certainly
a serious disadvantage for the application of those acylated
peptides as antiviral drugs.
Nevertheless, only the multiple presentations of antiviral
peptides, and the binding of peptides to HA can explain the
observed ability to aggregate viruses, which has been demon-
strated for all peptides except for the control peptide C18-rs2s.
We found that C18-PeBGF was able to inhibit Aichi H3N2 and
Rostock H7N1 virus induced hemagglutination at 1.2 µM and
2.8 µM, respectively. In comparison to unmodified PeBGF the
inhibitory potential was increased by 10 fold for Rostock H7N1
and by 20 fold for Aichi H3N2. In addition, we found enhanced
infection inhibition of C18-PeBGF compared to its non-acylated
form. Against Aichi H3N2 and Rostock H7N1 we determined
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IC50 values of 5.9 µM and 84 µM, respectively. Compared to
the monomeric peptide we could reduce the IC50 value by
5 fold against Aichi H3N2, whereas we did not observe
enhanced inhibitory potential in the infection experiments with
Rostock H7N1.
However, despite the principal potential of acylated antiviral
peptides such as C18-PeBGF to inhibit virus interaction with
cells, our observation of a strong affinity of those structures to
membranes, and also to incorporate into membranes are serious
disadvantages for their application as therapeutics. Indeed, we
found that the inhibition of virus mediated hemagglutination by
acylated antiviral peptides was drastically reduced in the pres-
ence of additional membranes (here liposomes). Taken into
consideration that the in vivo situation is characterized by an
excess of cell membrane surfaces serving as targets for the
amphiphilic peptides, the multivalent presentation of antiviral
peptides by respective nanostructures will be perturbed or even
inhibited.
In conclusion, the acylation of those peptides as used in our
study, and in previous studies does not resemble an advantage
over other strategies of multivalent presentations.
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